Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Flagstar Bank NA (FLG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Flagstar Bank NA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Flagstar Bank NA trades at $14.2 (market cap $5.89B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FLG | |
|---|---|---|
Market Cap | $29.60B | $5.89B |
Sector | Health | Financials |
52-Week High | $491.22 | $15.36 |
52-Week Low | $205.48 | $10.72 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
FLG trades at $14.21, up 1.43% today, with a bullish technical signal from moving averages. The stock shows a low P/B of 0.77 but a high P/E of 473, reflecting recent profitability after a 2025 net loss. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and declared dividends, signaling financial strength. Analyst consensus is a Buy with a $16.85 price target, indicating potential upside from current levels.
The outlook is cautiously optimistic, supported by analyst bullishness and strategic initiatives like technology transformation. Key risks include earnings volatility, competitive pressures in banking, and macroeconomic sensitivity. The stock presents a value opportunity based on price-to-book, but sustained earnings growth is crucial for justifying the elevated P/E ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
